The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting a strategic shift toward oncology, Pfizer and Arvinas have finalized a licensing agreement for the breast cancer treatment Veppanu with Rigel Pharmaceuticals. The deal stipulates a $70 million upfront payment to be shared between Arvinas and Pfizer. This development is part of Pfizer's broader effort to strengthen its drug pipeline as it navigates declining sales of COVID-19 related products and upcoming patent expirations.
This transaction aligns with Pfizer's aggressive expansion in the oncology sector, following its $43 billion acquisition of Seagen last year according to Reuters reports. In comparison to peers, companies like AstraZeneca and Merck are also intensifying focus on targeted cancer therapies, with Merck's Keytruda generating approximately $25 billion in 2023 revenue per company filings. While the $70 million upfront payment is modest for a mega-cap like Pfizer, it represents a calculated addition to its specialized treatment portfolio.
Sign in to access this content
Sign InRegarding market performance, PFE stock stood at $26.00 (close June 15, 2026), having reached a daily high of $26.42. Traders are monitoring support levels near the recent low of $25.98 per market data. Looking ahead, investors should watch for broader market volatility following recent US inflation data, alongside any further clinical trial updates from Pfizer regarding its newly licensed oncology assets.